J&J's strong foreign sales offset drops in U.S. pharma, consumer health

If Johnson & Johnson ($JNJ) had to rely on its U.S. sales for growth, its third-quarter report would be a big disappointment. The company's domestic business saw sales drop 3.7%, due to declines across the board in prescription drugs, consumer products and medical devices. Earnings fell, too, partly because of the U.S. weakness.

The good news is that earnings of $1.24 per share, excluding special items, beat analyst projections of $1.21. And international sales showed some major oomph, growing at a real rate of about 8%, or 16.4% including currency effects. Total revenues came in at $16 billion, an increase of 6.8%.

The pharma division saw an even greater lift from international sales: Real growth of 18.5% (27.5% with currency gains) versus a domestic drop of 6.1%. Overall, the division grew 9%, with strong showings from its HIV drug Prezista (37% growth), blood cancer drug Velcade (20% growth) and arthritis remedy Remicade (up 15%). Those gains were partly offset by a 91% drop in sales of the former blockbuster antibiotic Levaquin.

In a way it's a harbinger of things to come. Like its Big Pharma rivals, J&J is looking to emerging markets to help goose sales, now that growth in established markets has slowed almost to a halt.

Consumer health is still struggling to regain its feet. In the consumer division, OTC drug sales fell by 24%, thanks to ongoing recalls and manufacturing problems. During the earnings call, executives said J&J products lost "significant" market share to private-label brands while its quality problems kept branded products off store shelves, Bloomberg reports.

- read the J&J release
- see the Bloomberg article
- see the Reuters story

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.